Key facts
- Notable investors include Fongit, Pulsalys.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for TheraPPI Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for TheraPPI Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TheraPPI Bioscience
Operator of a biotechnology company intended to modify protein interactions in oncology, rare diseases, and inflammation. The company specializes in modifying protein interactions to overcome cancer drug resistance and to offer cures to rare diseases, enabling the healthcare industry to get novel methodologies to cure deceases efficiently.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2023
- Employees
- 5
- Website
- tppibio.com/
- Ownership
- Privately Held (backing)
TheraPPI Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TheraPPI Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TheraPPI Bioscience in its N-PORT filings yet. We sweep new filings monthly.